• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email
    SC 13G/A 1 tm2428381d6_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.1)*

     

    iBio, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    451033708

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.

    451033708

     

    1 Names of reporting persons
    ADAR1 Capital Management, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization   
    Texas

    Number of
    shares
    beneficially
    owned by each
    reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power

    966,298(1)

    7 Sole dispositive power
    0
    8 Shared dispositive power
    966,298(1)

    9 Aggregate amount beneficially owned by each reporting person
    966,298
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2)
    12 Type of reporting person (see instructions)
    OO

     

    (1) Includes (i) 443,113 shares of common stock, par value $0.001 per share (“Common Stock”) held by ADAR1 Partners, LP and (ii) 523,185 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. Excludes 832,955 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC., ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 9,149,470 shares of Common Stock of iBio, Inc. (the "Issuer") outstanding as of November 12, 2024 reported in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    2 

     

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    ADAR1 Capital Management GP, LLC
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization
    Texas

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    966,298(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    966,298(1)

    9 Aggregate amount beneficially owned by each reporting person
    966,298
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2)
    12 Type of reporting person (see instructions)
    OO

     

    (1) Includes (i) 443,113 shares of Common Stock by ADAR1 Partners, LP and (ii) 523,185 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. Excludes 832,955 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.
    (2) Based on 9,149,470 shares of Common Stock of the Issuer outstanding as of November 12, 2024 reported in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    3 

     

     

    CUSIP No. 451033708

     

    1 Names of reporting persons
    Daniel Schneeberger
    2 Check the appropriate box if a member of a group (see instructions)
    (a) ¨
    (b) x
    3 SEC use only
     
    4 Citizenship or place of organization
    Switzerland

    Number of
    shares
    beneficially
    owned by each reporting
    person with:
    5 Sole voting power
    0
    6 Shared voting power
    966,298(1)
    7 Sole dispositive power
    0
    8 Shared dispositive power
    966,298(1)

    9 Aggregate amount beneficially owned by each reporting person
    966,298
    10 Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
    ¨
    11 Percent of class represented by amount in Row (9)
    9.99%(2)
    12 Type of reporting person (see instructions)
    IN

     

    (1) Includes (i) 443,113 shares of Common Stock by ADAR1 Partners, LP and (ii) 523,185 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR1 Partners, LP as of November 5, 2024. Excludes 832,955 shares of Common Stock underlying pre-funded warrants and milestone warrants held by ADAR Partners, LP, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
    (2) Based on 9,149,470 shares of Common Stock of the Issuer outstanding as of November 12, 2024 reported in Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 12, 2024.

     

    4 

     

     

    Item 1(a) Name of issuer:

     

    iBio, Inc.

     

    Item 1(b) Address of issuer’s principal executive offices:

     

    11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121

     

    Item 2(a) Name of person filing:

     

    This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

      (i) ADAR1 Capital Management, LLC (“ADAR1 Capital Management”);
      (ii) ADAR1 Capital Management GP, LLC (“ADAR1 General Partner”); and
      (iii) Daniel Schneeberger (“Mr. Schneeberger”).

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.

     

    Item 2(c) Citizenship:

     

      (i) ADAR1 Capital Management is a Texas limited liability company;

    (ii)ADAR1 General Partner is a Texas limited liability company; and

    (iii)Mr.Schneeberger is a citizen of Switzerland.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

    Item 2(e) CUSIP No.:

     

    451033708

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

     

      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ☐ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); 

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); 

     

    5 

     

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); 

     

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

     

      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); 

     

      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); 

     

      (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). 

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

     

    Item 4. Ownership

     

    ADAR1 Capital Management, LLC

     

    Amount beneficially owned:   966,298 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   966,298 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   966,298 

     

    ADAR1 Capital Management GP, LLC  

     

    Amount beneficially owned:   966,298 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   966,298 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   966,298 

     

    Daniel Schneeberger  

     

    Amount beneficially owned:   966,298 
    Percent of class:   9.99%
    Number of shares as to which the Reporting Person has:     
    Sole power to vote or direct the vote:   0 
    Shared power to vote or direct the vote:   966,298 
    Sole power to dispose or direct the disposition of:   0 
    Shared power to dispose or direct the disposition of:   966,298 

     

    6 

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    7 

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      /s/ Daniel Schneeberger
    Daniel Schneeberger, in his individual capacity

     

    8 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.001 per share of iBio, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

     

    In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of November 14, 2024.

     

      ADAR1 CAPITAL MANAGEMENT, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      ADAR1 CAPITAL MANAGEMENT GP, LLC
       
      /s/ Daniel Schneeberger
      Daniel Schneeberger
      Manager
       
      /s/ Daniel Schneeberger
    Daniel Schneeberger, in his individual capacity

     

    9 

     

    Get the next $IBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on iBio with a new price target

      Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

      5/28/24 7:42:07 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

      11/29/21 7:34:24 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on iBio with a new price target

      JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

      11/29/21 7:32:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

      iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the initiation of a NHP study for its Activin E engineered antibody candidate, now

      6/16/25 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

      Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in Janu

      5/5/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal Third Quarter 2025 Financial Results

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. "During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "At the same time, we made significant strides in our pipeline, with promising non

      5/2/25 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    SEC Filings

    See more
    • iBio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - iBio, Inc. (0001420720) (Filer)

      6/18/25 7:22:17 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by iBio Inc.

      S-3 - iBio, Inc. (0001420720) (Filer)

      6/13/25 8:57:50 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by iBio Inc.

      D - iBio, Inc. (0001420720) (Filer)

      5/7/25 9:50:45 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Legal Officer Banjak Marc

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:01:30 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Duran Felipe

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:59 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Brenner Martin

      4 - iBio, Inc. (0001420720) (Issuer)

      2/24/25 6:00:12 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:37 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:34:02 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

      4 - iBio, Inc. (0001420720) (Issuer)

      1/13/25 4:33:31 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Financials

    Live finance-specific insights

    See more
    • iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

      – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

      3/27/24 7:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

      BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. "We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focus on developing innovative immunotherapies," said Tom Isett, Chairman & CEO of iBio. "Chief among these was the RubrYc asset acquisition, which provides us with a differentiated, AI-powered drug di

      9/27/22 4:10:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

      – Positions Company for leadership in AI-powered drug discovery – – Expands iBio's immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company's transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ("RubrYc") after it entered into a definitive asset purchase agreement (the

      9/21/22 8:30:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • iBio to Begin Trading on the Nasdaq Stock Exchange

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

      2/19/25 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Strengthens Board with Appointment of Two New Independent Directors

      SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

      11/25/24 8:00:00 AM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • iBio Reports Fiscal First Quarter 2025 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

      11/12/24 4:05:00 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by iBio Inc.

      SC 13G - iBio, Inc. (0001420720) (Subject)

      11/14/24 8:47:49 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by iBio Inc.

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      11/14/24 4:48:52 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by iBio Inc. (Amendment)

      SC 13G/A - iBio, Inc. (0001420720) (Subject)

      4/9/24 5:22:43 PM ET
      $IBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care